Skip Navigation



Annals of Oncology Advance Access published online on March 12, 2007
Annals of Oncology, doi:10.1093/annonc/mdm069
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
18/4/623    most recent
mdm069v1
Right arrow E-letters: Submit a response
Right arrow E-letters: View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Wannesson, L
Right arrow Articles by Keating, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wannesson, L
Right arrow Articles by Keating, A
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

review

Feasibility and safety of autotransplants with noncryopreserved marrow or peripheral blood stem cells: a systematic review

L Wannesson1,*, T Panzarella2, J Mikhael1 and A Keating1

1 Department of Medical Oncology and Hematology
2 Department of Biostatistics, Princess Margaret Hospital, University Health Network, University of Toronto, Ontario, Canada

* Correspondence to: Dr L. Wannesson, Department of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Avenue, Suite 5-224, M5G2M9, Toronto, Ontario, Canada. Tel: +1-416-946-4501 ext. 3248; Fax: +1-416-946-4530; E-mail: wannesson{at}gmail.com

The objective of this systematic review is to examine the feasibility and safety of autologous noncryopreserved stem-cell transplants. This technique avoids the cost of establishing and maintaining a cryopreservation facility and may be of value for transplant centers in regions with limited economic resources. The primary outcome was the graft failure rate. In addition, a detailed description of the high-dose therapy regimens employed was undertaken. Secondary outcomes were transplant-related mortality and neutrophil and platelet engraftments times. Sixteen well-conducted nonrandomized studies met the eligibility criteria. Only two cases of graft failure (0.36%) occurred among 560 assessable patients receiving high-dose therapy and autotransplant for non-Hodgkin's lymphoma, Hodgkin's lymphoma, multiple myeloma, germ-cell tumors and acute leukemias. The most traditional high-dose schedules were used, although often modified to shorter regimens. High-dose melphalan appeared especially useful given its short half-life and was used to treat multiple myeloma by most groups. Secondary outcomes were comparable to those reported in the most relevant studies addressing standard (cryopreserved) autotransplant. According to this study, the use of autologous noncryopreserved hematopoietic progenitors to support patients undergoing high-dose therapy is feasible and safe.

hematopoietic, liquid storage, non-cryopreserved, nonfrozen

Received for publication July 20, 2006. Revision received September 10, 2006. Accepted for publication September 14, 2006.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


E-letters:

Read all E-letters

Liquid storage of stem cell harvest at 4 degree C upto 8 days results in timely engraftment
Pankaj Malhotra, et al.
Annals of Oncology, 17 Jul 2007 [Full text]

Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.